Neurochemical Research

, Volume 32, Issue 3, pp 489–495 | Cite as

Pyrroloquinoline Quinone is a Potent Neuroprotective Nutrient Against 6-Hydroxydopamine-Induced Neurotoxicity

Original Paper

Abstract

Pyrroloquinoline quinone (PQQ), which is an essential nutrient, has been shown to act as an antioxidant. Reactive oxygen species (ROS) are thought to be responsible for neurotoxicity caused by the neurotoxin 6-hydroxydopamine (6-OHDA). In this study, we investigated the ability of PQQ to protect against 6-OHDA-induced neurotoxicity using human neuroblastoma SH-SY5Y. When SH-SY5Y cells were exposed to 6-OHDA in the presence of PQQ, PQQ prevented 6-OHDA-induced cell death and DNA fragmentation. Flow cytometry analysis using the ROS-sensitive fluorescence probe, dihydroethidium, revealed that PQQ reduced elevation of 6-OHDA-induced intracellular ROS. In contrast to PQQ, antioxidant vitamins, ascorbic acid and α-tocopherol, had no protective effect. Moreover, we showed that PQQ effectively scavenged superoxide, compared to the antioxidant vitamins. Therefore, our results suggest the protective effect of PQQ on 6-OHDA-induced neurotoxicity is involved, at least in part, in its function as a scavenger of ROS, especially superoxide.

Keywords

Pyrroloquinoline quinone Antioxidant 6-Hydroxydopamine Oxidative stress Neuroprotection 

Notes

Acknowledgments

This work was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (HHa).

References

  1. 1.
    Gallop PM, Paz MA, Fluckiger R, et al (1989) PQQ, the elusive coenzyme. Trends Biochem Sci 14:343–346PubMedCrossRefGoogle Scholar
  2. 2.
    Goodwin PM, Anthony C (1998) The biochemistry, physiology and genetics of PQQ and PQQ-containing enzymes. Adv Microb Physiol 40:1–80PubMedGoogle Scholar
  3. 3.
    Kumazawa T, Seno H, Urakami T, et al (1992) Trace levels of pyrroloquinoline quinone in human and rat samples detected by gas chromatography/mass spectrometry. Biochim Biophys Acta 1156:62–66PubMedGoogle Scholar
  4. 4.
    Killgore J, Smidt C, Duich L, et al (1989) Nutritional importance of pyrroloquinoline quinone. Science 245:850–852PubMedCrossRefGoogle Scholar
  5. 5.
    Steinberg FM, Gershwin ME, Rucker RB (1994) Dietary pyrroloquinoline quinone: growth and immune response in BALB/c mice. J Nutr 124:744–753PubMedGoogle Scholar
  6. 6.
    Zhang Y, Rosenberg PA (2002) The essential nutrient pyrroloquinoline quinone may act as a neuroprotectant by suppressing peroxynitrite formation. Eur J Neurosci 16:1015–1024PubMedCrossRefGoogle Scholar
  7. 7.
    Zhu BQ, Simonis U, Cecchini G, et al (2006) Comparison of pyrroloquinoline quinone and/or metoprolol on myocardial infarct size and mitochondrial damage in a rat model of ischemia/reperfusion injury. J Cardiovasc Pharmacol Ther 11:119–128PubMedGoogle Scholar
  8. 8.
    Nishigori H, Yasunaga M, Mizumura M, et al (1989) Preventive effects of pyrroloquinoline quinone on formation of cataract and decline of lenticular and hepatic glutathione of developing chick embryo after glucocorticoid treatment. Life Sci 45:593–598PubMedCrossRefGoogle Scholar
  9. 9.
    Jenner P (2003) Oxidative stress in Parkinson’s disease. Ann Neurol 53:S26–S38PubMedCrossRefGoogle Scholar
  10. 10.
    Sian J, Dexter DT, Lees AJ, et al (1994) Alterations in glutathione levels in Parkinson’s disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 36:348–355PubMedCrossRefGoogle Scholar
  11. 11.
    Cohen G, Heikkila RE (1974) The generation of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6-hydroxydopamine, dialuric acid, and related cytotoxic agents. J Biol Chem 249:2447–2452PubMedGoogle Scholar
  12. 12.
    Graham DG (1978) Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 14:633–643PubMedGoogle Scholar
  13. 13.
    Hastings TG (1995) Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J Neurochem 64:919–924PubMedCrossRefGoogle Scholar
  14. 14.
    Bensadoun JC, Mirochnitchenko O, Inouye M, et al (1998) Attenuation of 6-OHDA-induced neurotoxicity in glutathione peroxidase transgenic mice. Eur J Neurosci 10:3231–3236PubMedCrossRefGoogle Scholar
  15. 15.
    Andrew R, Watson DG, Best SA, et al (1993) The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls. Neurochem Res 18:1175–1177PubMedCrossRefGoogle Scholar
  16. 16.
    Glinka Y, Gassen M, Youdim MB (1997) Mechanism of 6-hydroxydopamine neurotoxicity. J Neural Transm Suppl 50:55–66PubMedGoogle Scholar
  17. 17.
    Gassen M, Gross A, Youdim MBH (1998) Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6-hydroxydopamine. Mov Disord 13:242–248PubMedCrossRefGoogle Scholar
  18. 18.
    Soto-Otero R, Mendez-Alvarez E, Hermida-Ameijeiras A, et al (2000) Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson’s disease. J Neurochem 74:1605–1612PubMedCrossRefGoogle Scholar
  19. 19.
    Hara H, Ohta M, Ohta K, et al (2003) Apomorphine attenuates 6-hydroxydopamine-induced apoptotic cell death in SH-SY5Y cells. Redox Rep 8:193–197PubMedCrossRefGoogle Scholar
  20. 20.
    Hara H, Ohta M, Ohta K, et al (2003) Increase of antioxidative potential by tert-butylhydroquinone protects against cell death associated with 6-hydroxydopamine-induced oxidative stress in neuroblastoma SH-SY5Y cells. Brain Res Mol Brain Res 119:125–131PubMedCrossRefGoogle Scholar
  21. 21.
    Munoz FJ, Opazo C, Gil-Gomez G, et al (2002) Vitamin E but not 17beta-estradiol protects against vascular toxicity induced by beta-amyloid wild type and the Dutch amyloid variant. J Neurosci 22:3081–3089PubMedGoogle Scholar
  22. 22.
    Asanuma M, Hirata H, Cadet JL (1998) Attenuation of 6-hydroxydopamine-induced dopaminergic nigrostriatal lesions in superoxide dismutase transgenic mice. Neuroscience 85:907–917PubMedCrossRefGoogle Scholar
  23. 23.
    Choi WS, Yoon SY, Oh TH, et al (1999) Two distinct mechanisms are involved in 6-hydroxydopamine- and MPP+-induced dopaminergic neuronal cell death: role of caspases, ROS, and JNK. J Neurosci Res 57:86–94PubMedCrossRefGoogle Scholar
  24. 24.
    Barkats M, Millecamps S, Bilang-Bleuel A, et al (2002) Neuronal transfer of the human Cu/Zn superoxide dismutase gene increases the resistance of dopaminergic neurons to 6-hydroxydopamine. J Neurochem 82:101–109PubMedCrossRefGoogle Scholar
  25. 25.
    Callio J, Oury TD, Chu CT (2005) Manganese superoxide dismutase protects against 6-hydroxydopamine injury in mouse brains. J Biol Chem 280:18536–18542PubMedCrossRefGoogle Scholar
  26. 26.
    He K, Nukada H, Urakami T, et al (2003) Antioxidant and pro-oxidant properties of pyrroloquinoline quinone (PQQ): implications for its function in biological systems. Biochem Pharmacol 65:67–74PubMedCrossRefGoogle Scholar
  27. 27.
    Jensen FE, Gardner GJ, Williams AP, et al (1994) The putative essential nutrient pyrroloquinoline quinone is neuroprotective in a rodent model of hypoxic/ischemic brain injury. Neuroscience 62:399–406PubMedCrossRefGoogle Scholar
  28. 28.
    Zhang Y, Feustel PJ, Kimelberg HK (2006) Neuroprotection by pyrroloquinoline quinone (PQQ) in reversible middle cerebral artery occlusion in the adult rat. Brain Res 1094:200–206PubMedCrossRefGoogle Scholar
  29. 29.
    Otero P, Viana M, Herrera E, et al (1997) Antioxidant and prooxidant effects of ascorbic acid, dehydroascorbic acid and flavonoids on LDL submitted to different degrees of oxidation. Free Radic Res 27:619–626PubMedCrossRefGoogle Scholar
  30. 30.
    Choi HY, Song JH, Park DK, et al (2000) The effects of ascorbic acid on dopamine-induced death of PC12 cells are dependent on exposure kinetics. Neurosci Lett 296:81–84PubMedCrossRefGoogle Scholar
  31. 31.
    Heikkila RE, Cohen G (1973) 6-Hydroxydopamine: evidence for superoxide radical as an oxidative intermediate. Science 181:456–457PubMedCrossRefGoogle Scholar
  32. 32.
    Hamagishi Y, Murata S, Kamei H, et al (1990) New biological properties of pyrroloquinoline quinone and its related compounds: inhibition of chemiluminescence, lipid peroxidation and rat paw edema. J Pharmacol Exp Ther 255:980–985PubMedGoogle Scholar
  33. 33.
    Misra HS, Khairnar NP, Barik A, et al (2004) Pyrroloquinoline-quinone: a reactive oxygen species scavenger in bacteria. FEBS Lett 578:26–30PubMedCrossRefGoogle Scholar
  34. 34.
    Urakami T, Yoshida C, Akaike T, et al (1997) Synthesis of monoesters of pyrroloquinoline quinone and imidazopyrroloquinoline, and radical scavenging activities using electron spin resonance in vitro and pharmacological activity in vivo. J Nutr Sci Vitaminol (Tokyo) 43:19–33Google Scholar
  35. 35.
    Hara H, Ohta M, Adachi T (2006) Apomorphine protects against 6-hydroxydopamine-induced neuronal cell death through activation of the Nrf2-ARE pathway. J Neurosci Res 84:860–866PubMedCrossRefGoogle Scholar
  36. 36.
    Yamaguchi K, Sasano A, Urakami T, et al (1993) Stimulation of nerve growth factor production by pyrroloquinoline quinone and its derivatives in vitro and in vivo. Biosci Biotechnol Biochem 57:1231–1233PubMedCrossRefGoogle Scholar
  37. 37.
    Murase K, Hattori A, Kohno M, et al (1993) Stimulation of nerve growth factor synthesis/secretion in mouse astroglial cells by coenzymes. Biochem Mol Biol Int 30:615–621PubMedGoogle Scholar
  38. 38.
    Aizenman E, Hartnett KA, Zhong C, et al (1992) Interaction of the putative essential nutrient pyrroloquinoline quinone with the N-methyl-d-aspartate receptor redox modulatory site. J Neurosci 12:2362–2369PubMedGoogle Scholar
  39. 39.
    Naarala J, Nykvist P, Tuomala M, et al (1993) Excitatory amino acid-induced slow biphasic responses of free intracellular calcium in human neuroblastoma cells. FEBS Lett 330:222–226PubMedCrossRefGoogle Scholar
  40. 40.
    Sun D, Murali SG (1998) Stimulation of Na+–K+–2Cl cotransporter in neuronal cells by excitatory neurotransmitter glutamate. Am J Physiol 275:C772–C779PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Hirokazu Hara
    • 1
  • Hideaki Hiramatsu
    • 1
  • Tetsuo Adachi
    • 1
  1. 1.Department of Clinical PharmaceuticsGifu Pharmaceutical UniversityGifuJapan

Personalised recommendations